Zim Laboratories Limited
Incorporated in 1989, Zim LaboratoriesLtd manufactures formulation drugs andpre formulation ingredients in India andmarkets and sells these within and outside India
What Zim files
- Others74
- Investor Meet33
- Important19
- Board Meeting13
- Updates9
- JV/Acquisition6
Zim Laboratories' Q1 FY27 Total Operating Income grew 31.2% YoY to ₹94.2 Cr. EBITDA dropped 40% to ₹3.4 Cr (3.7% margin) due to higher costs, resulting in a ₹4.0 Cr net loss. Innovative product revenue tripled YoY to ₹13.8 Cr. CAPA remediation is largely complete, with 17 filings and 10...
Zim Laboratories Limited has informed the Exchange about letter send to members providing web link of Annual Report FY 25-26
Zim Laboratories saw FY26 operating income at ₹374.4 Cr, EBITDA at ₹41.4 Cr, impacted by geopolitical issues. The company secured 34 Marketing Authorizations, expanded leadership, and saw successful CAPA remediation. A ₹35 Cr preferential share issue was approved, strengthening its innovative product pipeline.
ZIM Laboratories' European unit secured Marketing Authorization for Dabigatran Etexilate capsules in Italy. This unlocks the EU market, valued at ~$392.84 Million USD (2025), with Italy contributing ~$60.91 Million USD. Positive for commercialization.
ZIM Labs' manufacturing facility has successfully completed its EU GMP inspection by German and Portuguese authorities. This compliance milestone is critical for maintaining access to European markets and ensuring high quality standards.